Answers are grounded in this paper and cite their sources.
Pemigatinib blocks FGF2-induced signaling and 3D outgrowth of D2.OR cells via inhibition of FGFR1.
No takes yet. Share an insight, caveat, or question.
Kulkoyluoglu‐Cotul et al. (2024) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: